TY  - CHAP
M1  - Book, Section
TI  - Ketolides
A1  - Gruenberg, Katherine
A1  - Guglielmo, B. Joseph
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
PY  - 2020
T2  - Current Medical Diagnosis and Treatment 2020
AB  - Telithromycin,  the  one  available  ketolide,  is  similar  in  structure  to  macrolides  but  has  a  broader  spectrum  of  activity.  Telithromycin  offers  activity  against  both  penicillin-resistant  and  macrolide-resistant  pneumococci  and  is  equal  to  azithromycin  against  atypical  pathogens  and  H  influenzae.  The  dose  is  800  mg/day  orally,  and  no  adjustment  is  needed  for  kidney  disease  or  liver  insufficiency.  Telithromycin  has  been  associated  with  severe  hepatotoxicity  resulting  in  liver  transplant  and  death.  Telithromycin  also  has  been  found  to  exacerbate  myasthenia  gravis.  Cytochrome  P450  inhibition  with  telithromycin  approximates  that  of  erythromycin,  and  increased  serum  levels  of  warfarin  and  other  agents  would  be  expected  with  concomitant  administration  of  telithromycin.  The  serious  hepatotoxicity  of  telithromycin  significantly  limits  its  use  in  the  treatment  of  outpatient  respiratory  tract  infection.  There  is  no  clear  indication  for  this  agent  presently.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2022/05/28
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1165970407
ER  -